pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,633 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT786Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a ‘forced’ McKinsey collaboration
    Who controls the Medicaid market, GLP-1 usage and pizza household costs, and more from Health Care Inc.
    STAT · 28d ago↗ source
  • STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
    The panel will soon consider whether to relax restrictions on certain peptides.
    STAT · 28d ago↗ source
  • Zymeworks CEO on why the Theravance deal is value for money
    On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
    Endpoints · 28d ago
← prev
page 23 of 66
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • BioCryst ends internal discovery programs, will close Alabama research facility
    BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal di…
    Endpoints · 28d ago↗ source
  • Evommune's lead drug fails in chronic hives, stock sinks
    Evommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin cond…
    Endpoints · 28d ago↗ source
  • Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
    Plus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisit…
    Endpoints · 28d ago↗ source
  • Post-Hoc: China deals are pharma’s new tax inversions
    About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...
    Endpoints · 28d ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 28d ago↗ source
  • De-Risking a Rare Disease Launch Starts with Precision
    Why traditional models fall short in rare disease commercialization—and what works instead.
    Fierce Biotech · 1mo ago↗ source
  • Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
    Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…
    Endpoints · 1mo ago↗ source
  • Opinion: Why the space in ‘health care’ matters
    When STAT polled our readers on ‘health care’ vs. ‘healthcare,’ about 60% of our readers voted for one word.
    STAT · 1mo ago↗ source
  • Opinion: STAT readers debate blue zones, open-access publishing fees, and more
    Keep those letters coming!
    STAT · 1mo ago↗ source
  • Endpoints News History: 10 Years, Bootstrap to FT
    Ten years of Endpoints News: no investors, a 50/50 split, profitable from day one. Co-founders Arsalan Arif and John Carroll on how the partnership held.
    Endpoints · 1mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 1mo ago↗ source
  • US government launches probe into Germany's plan to pay less for drugs
    Amid Germany's ongoing review of its healthcare spending, the US government has started a trade investigation into the European country's drug pricing system. The investigation, under Section 301…
    Endpoints · 1mo ago↗ source
  • Opinion: Maternity deserts aren’t accidents. They’re the result of a design flaw
    Shrinking fertility should mean less strain on doctors. But nearly half of U.S. counties lack a practicing obstetrician or gynecologist.
    STAT · 1mo ago↗ source
  • Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginning
    The co-founders of Darwin Health write that the real work for making dramatic gains against pancreatic cancers is just beginning.
    STAT · 1mo ago↗ source
  • Tennessee pharmacies sell potent ivermectin, led by anti-vaccine doctor who’s taken ‘bucketloads’
    Tennessee pharmacies are selling potent versions of the antiparasitic drug ivermectin, led by an anti-vaccine doctor who’s taken "bucketloads."
    STAT · 1mo ago↗ source
  • Federal grant delays could jeopardize essential disability services, research
    Disability researchers across the country worry about their jobs, and the future of their institutions, as a delay in issuing federal grants drags on.
    STAT · 1mo ago↗ source
  • STAT+: CMS recalculates Medicare Advantage star ratings again, adding more volatility to program
    Medicare Advantage plans that receive four out of five stars or better get bonus payments, which have ballooned to $16 billion this year.
    STAT · 1mo ago↗ source
  • STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
    A panel of advisers to FDA gave its endorsement to a seasonal mRNA flu vaccine that was developed by Moderna and that earlier this year became the subject of controversy.
    STAT · 1mo ago↗ source
  • STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data
    Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program.
    STAT · 1mo ago↗ source
  • STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data
    Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program.
    STAT · 1mo ago↗ source
  • New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises
    This week on "The Readout LOUD" podcast: new hope in treating Huntington's disease and a report card on RFK Jr.'s promises. Listen now.
    STAT · 1mo ago↗ source
  • FDA vaccine advisors unanimously support Moderna's flu shot
    Every member of a vaccine advisory panel for the FDA voted in favor of Moderna’s flu vaccine, after the product faced roadblocks from previous agency leadership. The Vaccines and Related Biologic…
    Endpoints · 1mo ago↗ source